Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    REVIRAL REVC006
Previous Study | Return to List | Next Study

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV (REVIRAL2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04267822
Recruitment Status : Recruiting
First Posted : February 13, 2020
Last Update Posted : October 5, 2021
Sponsor:
Information provided by (Responsible Party):
ReViral Ltd

Tracking Information
First Submitted Date  ICMJE February 5, 2020
First Posted Date  ICMJE February 13, 2020
Last Update Posted Date October 5, 2021
Actual Study Start Date  ICMJE June 15, 2020
Estimated Primary Completion Date June 30, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 11, 2020)
  • Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC) during the study [ Time Frame: Pre-dose baseline (Day 1) through Visit 8 (Day 28) ]
    Progression to LRTC during the study defined as one of the following:
    • Primary LRTI caused by RSV
    • Secondary bacterial LRTI
    • LRTI caused by another pathogen
    • LRTC of unknown etiology
  • Change in RSV nasal viral load (via RT-qPCR) [ Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28) ]
    RSV change measured by the time-weighted average (DAVG) viral load using RT qPCR
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 11, 2020)
  • Percent of participants who experience AEs, TEAEs, SAEs and withdrawals due to TEAEs [ Time Frame: First dose of study drug through Visit 8 (Day 28) ]
    Safety analyses will include a summary of AEs, including but not limited to n (%) of subjects in each treatment group and overall.
  • Evaluate safety and tolerability of RV521 by assessing changes from baseline in systolic and diastolic BP (vital sign parameters) [ Time Frame: Baseline through Visit 8 (Day 28) ]
    BP will be collected in mm Hg. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
  • Evaluate safety and tolerability of RV521 by assessing changes from baseline in body temperature (vital sign parameters) [ Time Frame: Baseline through Visit 8 (Day 28) ]
    Body Temperature will be collected in degrees Fahrenheit (°F) or degrees Celsius (°C). Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
  • Evaluate safety and tolerability of RV521 by assessing changes from baseline in respiration rate (vital sign parameters) [ Time Frame: Baseline through Visit 8 (Day 28) ]
    Respiration rate will be measured in breaths per minute. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
  • Evaluate safety and tolerability of RV521 by assessing changes from baseline in pulse/heart rate (vital sign parameters) [ Time Frame: Baseline through Visit 8 (Day 28) ]
    Heart rate will be measured in beats per minute. Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
  • Evaluate safety and tolerability of RV521 by assessing changes from baseline weight/BMI [ Time Frame: Baseline through Visit 8 (Day 28) ]
    Weight and height will be collected and combined to report BMI
  • Evaluate the proportion of subjects with changes and shifts in hematology/clinical chemistry/urinalysis laboratory values (laboratory tests read by a central lab) from baseline. [ Time Frame: Collected at Visit 2/Day 1 (pre-dose), Visit 4/Day 3, Visit 6/Day 14 and Visit 8/Day 28 ]
    Results at each visit will be summarized using the statistics n, mean, standard deviation, median, minimum and maximum. Also, change from baseline will also be summarized by post baseline visits.
  • Evaluate the proportion of subjects with changes in ECG measurements and changes in clinical impression from baseline [ Time Frame: Measurements will be taken at Day 1/Visit 2 (pre-dose and at 5-hours post-dose), on Day 3/Visit 4 (at 5 hours post-dose), and at Visit 6 (Day 14) ]
    ECGs will be taken with a centrally supplied ECG machine and electronically transmitted to a central ECG repository. ECG will only be evaluated by the Investigator for normal, abnormal NCS and abnormal CS. Parameters collected will be:
    • Ventricular Heart Rate (bpm)
    • PR Interval (msec)
    • QRS Interval (msec)
    • QT Interval (msec)
    • QTcB Interval (msec)
    Results at each visit will be summarized using the statistics: n (number of observations), mean, SD, median, minimum and maximum.
  • Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by RT-qPCR [ Time Frame: Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28) ]
    Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory. Viral load will be assessed at intervals from nasal swabs by RT-qPCR.
  • Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by CBIA [ Time Frame: Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28) ]
    Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory. Viral load will be assessed at intervals from nasal swabs by CBIA.
  • Mean change in RSV viral load assessed via CBIA [ Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28) ]
    change measured by the time weighted average (DAVG) viral load using CBIA
  • Mean change from baseline in viral RNA shedding [ Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28) ]
    RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.
  • Proportion of subjects who no longer shed RSV assessed by both RT-qPCR and CBIA at each timepoint [ Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28) ]
    RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.
  • Time to improvement in RSV-related symptoms [ Time Frame: Daily from baseline (Day 1) through Visit 8 (Day 28) ]
    Defined as all symptoms present at initiation of therapy are mild or no longer present. (absent/resolved)
  • Time to total resolution of all RSV-related symptoms [ Time Frame: Daily from baseline (Day 1) through Visit 8 (Day 28) ]
    Defined as all symptoms are no longer present.
  • Proportion of days with lowest daily SpO2 ≥ 90% on room air [ Time Frame: Daily from baseline (Day 1) through Visit 8 (Day 28) ]
    SpO2 measured at every visit. For subjects on oxygen or who are mechanically ventilated may have this waived.
  • Number of days where supplementary oxygen was required [ Time Frame: Baseline (Day 1) through Visit 8 (Day 28) ]
    Use of daily supplementary oxygen will be collected throughout the study.
  • Proportion of subjects who require hospitalization during the study [ Time Frame: Baseline (Day 1) through Visit 8 (Day 28) ]
    Daily hospitalization utilization will be collected
  • Mean number of days of hospitalization during the study [ Time Frame: Baseline (Day 1) through Visit 8 (Day 28) ]
    Daily hospitalization utilization will be collected
  • Proportion of subjects requiring ICU [ Time Frame: Baseline (Day 1) through Visit 8 (Day 28) ]
    Daily ICU utilization will be collected
  • Mean number of days in ICU [ Time Frame: Baseline (Day 1) through Visit 8 (Day 28) ]
    Daily ICU utilization will be collected
  • Proportion of subjects requiring mechanical ventilation [ Time Frame: Baseline (Day 1) through Visit 8 (Day 28) ]
    Daily mechanical ventilation requirements will be collected
  • Number of subjects who experience death (all-cause mortality) [ Time Frame: First dose of study drug through Visit 8 (Day 28) ]
    Patient outcome will be followed and collected
  • Number of subjects who experience death attributable to LRTC [ Time Frame: First dose of study drug through Visit 8 (Day 28) ]
    Patient outcome will be followed and collected
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV
Official Title  ICMJE Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, and Efficacy of RV521 in the Treatment of Adult Subjects Who Have Undergone Hematopoietic Cell Transplantation (HCT) With a Documented Upper Respiratory Tract Infection (URTI) With Respiratory Syncytial Virus (RSV)
Brief Summary RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.
Detailed Description

The purpose of this study is to compare the viral load, safety, tolerability, and clinical efficacy of RV521 compared to placebo. This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study. Up to 200 adult subjects with a documented symptomatic RSV URTI who have undergone HCT within 1 year of randomization and who are moderately to severely immunocompromised will be randomized.

Qualified subjects will be randomized in a 1:1 ratio to receive RV521 capsules or matching placebo twice daily for 10 days. After the completion of the 10-day double-blind treatment period, subjects will be followed for an additional 28 days. Study drug may be taken on an outpatient or inpatient basis, depending on clinical status and site practices. Randomization will be stratified by type of HCT graft and ALC count. There are 9 clinic visits planned for this study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
A Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The Investigators, Sponsor, Independent Adjudication Committee members, and any personnel involved in the subject's care, assessment, monitoring, data collection, or analysis will be blinded to the subject treatment assignment throughout the conduct of the study. Exceptions to this are limited to a fire-walled-protected, unblinded Data Safety Monitoring Board (DSMB) statistician at the Contract Research Organization (CRO) who will prepare output for the closed session of all DSMB meetings.
Primary Purpose: Treatment
Condition  ICMJE
  • RSV Infection
  • Stem Cell Transplant Complications
  • Lower Resp Tract Infection
Intervention  ICMJE
  • Drug: RV521 oral tablet
    Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
    Other Name: sisunatovir
  • Drug: Placebo oral tablet
    Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
    Other Name: vehicle
Study Arms  ICMJE
  • Experimental: RV521 Capsules
    RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
    Intervention: Drug: RV521 oral tablet
  • Placebo Comparator: RV521 Placebo Capsules
    RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.
    Intervention: Drug: Placebo oral tablet
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 11, 2020)
200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 31, 2023
Estimated Primary Completion Date June 30, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Has undergone autologous or allogeneic HCT using any conditioning regimen within 1 year of randomization. Subjects who have undergone HCT more than 1 year before Randomization are eligible if all other inclusion/exclusion criteria are satisfied and under at least one of the following conditions:

    1. Diagnosed with Chronic Graft-vs-Host Disease (GVHD), or
    2. Has used systemic corticosteroids in the 30 days prior to RSV infection
  2. Has moderate to severe immunocompromise, defined as a score ≥ 5 on the ISI-RSV and/or an ALC of ≤ 500 cells/ mm3
  3. Documentation of positive RSV infection in the upper airway

Exclusion Criteria:

  1. Use of non-marketed investigational agents within 30 days, OR use of an investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT.
  2. Receiving a prescription, OTC, or herbal medication that is a potent inducer or inhibitor of CYP3A4, within 2 weeks of Randomization.
  3. Receiving a prescription, OTC, or herbal medication that is a substrate of CYP3A4 with a narrow therapeutic index where monitoring blood levels is not possible.
  4. Known chronic infection with hepatitis B, C, or HIV.
  5. Is in the pre-engraftment period during RSV infection.
  6. Admitted to the hospital primarily for lower respiratory tract disease of any cause as determined by the Investigator.
  7. Any condition requiring mechanical ventilation or vasopressor support at the time of randomization.
  8. Clinically significant bacteremia or fungemia within 5 days prior to Screening that has not been adequately treated.
  9. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated.
  10. Excessive nausea/vomiting at Screening or an inability to swallow capsules.
  11. Elevation of hepatic enzymes or renal compromise.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Heather Welch, MPhil +441438906760 hwelch@reviral.co.uk
Contact: Melanie Klotz 919-806-4445 mklotz@reviral.com
Listed Location Countries  ICMJE Australia,   Brazil,   Korea, Republic of,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04267822
Other Study ID Numbers  ICMJE REVC006
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party ReViral Ltd
Original Responsible Party Same as current
Current Study Sponsor  ICMJE ReViral Ltd
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Seth Hetherington, MD ReViral Ltd
PRS Account ReViral Ltd
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP